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Leprosy, a chronic mycobacterial infection caused 
by the obligate intracellular pathogen Mycobacterium 
leprae, mainly damages the skin and nerves. Patients 
experience an extraordinary array of cutaneous lesions, 
peripheral neuropathy and anaesthesia with related dis-
figurement, deformity and disability along with the so-
cial stigma associated with this disease (Scollard et al. 
2006). Despite the enormous success of worldwide lep-
rosy control programs since the widespread implemen-
tation of multidrug therapy (MDT) in the mid-1980s, 
228,474 new cases were recorded in 2010 among the 130 
countries reporting, with 9% of these cases in children 
and 5.8% of cases presenting with advanced grade-2 dis-
ability (WHO 2011). Although it is generally accepted 
that the majority of cases are spread through contact 
with those with untreated multibacillary (MB) disease 
or with individuals with subclinical undiagnosed lepro-
sy, little is known about the true distribution of this dis-
ease and what factors are important in the transmission 
and progression of symptoms in susceptible individuals. 
It is known is that the rates of M. leprae infection are 
likely many times greater than indicated in newly re-
ported case trends and that leprosy will remain a health 
problem for the foreseeable future in many parts of the 
world (Meima et al. 2004, Moet et al. 2008).
An “Enhanced global strategy for further reducing 
the disease burden due to leprosy (plan period: 2011-
2015)” (WHO 2009) is being implemented by leprosy 
control programs in countries in which leprosy is en-
demic. The World Health Organization has set a global 
targeted reduction of new cases of grade-2 disability by 
≥ 35% by the end of 2015 compared to baseline levels 
recorded at the end of 2010. To achieve this goal, the 
leprosy control programs will need to reduce the delay 
in disease diagnosis, administer MDT promptly, ensure 
that patients fully complete their treatment and confirm 
during follow-up that patients are cured. Together, these 
actions should impact the transmission of M. leprae in the 
community and decrease the cases of visible disability. 
However, achieving this goal has been made more diffi-
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Although leprosy is curable with drug treatment, the identification of biomarkers of infection, disease progression 
and treatment efficacy would greatly help to reduce the overall prevalence of the disease. Reliable biomarkers would 
also reduce the incidence of grade-2 disability by ensuring that those who are most at risk are diagnosed and treated 
early or offered repeated treatments in the case of relapse. In this study, we examined the reactivity of sera from lep-
romatous and tuberculoid leprosy patients (LPs) against a panel of 12 recombinant Mycobacterium leprae proteins and 
found that six proteins were strongly recognised by multibacillary (MB) patients, while only three were consistently rec-
ognised by paucibacillary patients. To better understand the dynamics of patient antibody responses during and after 
drug therapy, we measured antibody titres to four recombinant proteins, phenolic glycolipid-I and lipoarabinomannan 
at baseline and up to two years after diagnosis to investigate the temporal changes in the antibody titres. Reactivity pat-
terns to individual antigens and decreases in antibody titres were patient-specific. Antibody titres to proteins declined 
more rapidly vs. those to carbohydrate and glycolipid antigens. Compared to baseline values, increases in antibody 
titres were observed during reactional episodes in one individual. Additionally, antibody responses against a subset of 
antigens that provided a good prognostic indicator of disease progression were analysed in 51 household contacts of 
MB index cases for up to two years. Although the majority of these contacts showed no change or exhibited decreases in 
antibody titres, seven individuals developed higher titres towards one or more of these antigens and one individual with 
progressively higher titres was diagnosed with borderline lepromatous leprosy 19 months after enrolment. The results 
of this study indicate that antibody titres to specific M. leprae antigens can be used to monitor treatment efficacy in LPs 
and assess disease progression in those most at risk for developing this disease. 
Key words: biomarkers - leprosy - serology - recombinant proteins - household contacts
Serological biomarkers for leprosy • John S Spencer et al.80
cult by the integration of leprosy control into the general 
health delivery network in many countries and a reduc-
tion in the number of trained leprologists and laboratory 
technicians, which has led to an increase in misdiagnosis 
and a failure to treat early and appropriately. A definitive 
diagnosis still relies on clinical observations and time-
consuming invasive tests to confirm the presence of 
acid-fast bacilli (AFB) in slit skin smears or immunop-
athological changes in the biopsies of skin lesions. Such 
services may be lacking in resource-poor settings. The 
development of a simple serological test that could be 
easily deployed in the field to identify those individuals 
at highest risk of succumbing to leprosy would improve 
early diagnosis and potentially break the lines of trans-
mission to help reduce the rate of grade-2 disability.
We examined the serological responses of 21 untreat-
ed MB leprosy patients (LPs) and nine untreated pauc-
ibacillary (PB) LPs at diagnosis (baseline) against a pan-
el of 12 recombinant proteins and the native M. leprae 
cytosolic fraction [M. leprae soluble antigen (MLSA)] to 
assess serological reactivity patterns across the clinical 
spectrum. Antibody titres in 12 of the MB cases were 
examined for at least two years after beginning MDT 
to understand the dynamics of the antibody response 
to recombinant M. leprae proteins, lipoarabinomannan 
(LAM) and phenolic glycolipid-I (PGL-I) antigens. In 
addition, 51 contacts of MB index cases were assessed for 
the same antibody responses against a subset of key anti-
gens to identify any response patterns that can be used to 
identify those most likely to develop disease symptoms. 
The antibody titres in household contact (HHC) group 
were also followed longitudinally for most individuals for 
at least two years and several HHC developed progres-
sively higher antibody titres during this period. One of 
these HHC was diagnosed with borderline lepromatous 
(BL) leprosy at an early stage during routine follow-up 
after increasing titre results were provided to the clinical 
staff at the Cebu Skin Clinic. Our results suggest that 
incorporation of simple and objective serological tests to 
monitor changes in antibody titres in HHC that have the 
highest risk of M. leprae infection could be an effective 
strategy to identify patients with early disease progres-
sion. Serological tests will lead to more rapid diagnosis 
and treatment prior to the development of the advanced 
disease, which will have a profound effect on reducing 
neurologic impairment and grade-2 disability. 
SUBJECTS, MATERIALS AND METHODS
Subjects and samples - LPs [2 BL (designated MB-3 
and MB-7) and 10 lepromatous (LL) patients] were di-
agnosed at the Cebu Skin Clinic and Leonard Wood 
Memorial (LWM) Center for Leprosy Research, Cebu, 
Philippines, based on histological findings and clinical 
observations determined by experienced leprologists and 
a leprosy pathologist as previously described (Spencer et 
al. 2011). Patients were categorised according to the Rid-
ley-Jopling classification (Ridley & Jopling 1966). Bacte-
rial indices (BI) were determined (a measure of the num-
ber of AFB found in the dermis based on a logarithmic 
scale from 0 at the tuberculoid end of the spectrum to 6+ 
at the lepromatous end of the spectrum) and patient sera 
were collected at the time of diagnosis prior to beginning 
MDT. Except for one individual who developed dapsone 
sensitivity, patients were then placed on standard MDT 
and returned for follow-up bleeds at months 1, 2, 3, 6, 9 
and 12 and every three months thereafter until at least 
two years post-diagnosis. MB patients received WHO-
recommended MDT for one year with the following 
three-drug regimen: 600 mg rifampicin once per month, 
300 mg clofazimine during the first month followed by 
50 mg daily and 100 mg dapsone daily. The patient who 
developed dapsone sensitivity received 400 mg ofloxacin 
once per month instead of dapsone. Patients who experi-
enced reactional states (type 1 reversal reaction or type 
2 erythema nodosum leprosum) were treated with 20-40 
mg prednisone per day with 5 mg decreases every two 
weeks once neuritis and lesion swelling subsided. The 20 
mg dose was prescribed for reactions without neuritis, 
while the 40 mg dose was used for reactions with neu-
ritis. The timing and duration of the reactional episodes 
were recorded. Additional borderline tuberculoid (BT)/
tuberculoid (TT) (n = 3) and BL/LL (n = 9) LP sera came 
from well-characterised samples that had been analysed 
in a previous study (Spencer et al. 2011). 
HHC were defined as individuals who resided with 
an untreated MB index case for at least six months at 
the time of diagnosis. Most HHCs were related in some 
way to the index case (most commonly spouse, parent 
or sibling). Between one-four HHCs were enrolled for 
each index case. A total of 51 contacts of 21 MB patients 
(including the aforementioned 12 MB patients enrolled 
to assess the effect of MDT on antibody responses) were 
enrolled after identifying the index case. All HHCs were 
thoroughly examined and deemed healthy and without 
any clinical signs or symptoms of the disease at the time 
of enrolment. A baseline serum sample and follow-up 
bleeds were obtained every three months for at least two 
years after enrolment, during which each contact was 
examined for any signs or symptoms of the disease at 
follow-up visits. Serum samples from all sources were 
anonymised and coded to protect donor identities and 
were obtained with informed consent and/or with per-
mission from the institutional review board of LWM. 
All procedures were in accordance with the ethical 
standards of the Helsinki Declaration of 1975 (revised 
in 1983) regarding human subjects. Sample collection 
from patients and HHC began in April 2009 and was 
completed in December 2011. The characteristics of the 
individuals in the study groups are listed in Table I. 
Cloning and purification of recombinant M. leprae 
proteins - DNA sequences encoding 12 full-length M. le-
prae proteins were cloned from genomic DNA as previ-
ously described (Spencer et al. 2005, Reece et al. 2006). 
Purified recombinant proteins were produced by the 
Infectious Disease Research Institute (IDRI), Seattle, 
WA or Colorado State University (CSU), Fort Collins, 
CO, USA. The proteins from IDRI that were selected 
for investigation included ML0411, ML2055, ML0091, 
ML0405 and leprosy IDRI diagnostic (LID-1), which 
is a fusion protein of ML2331 and ML0405. The proteins 
from CSU that were selected were ML2028, ML2038, 
ML1795, ML0557, ML0380, ML0286 and ML0050. 
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Other antigens - The disaccharide epitope of PGL-I 
was synthesised and coupled to bovine serum albu-
min (ND-O-BSA) as previously described (Cho et al. 
1984) with modifications (Zhang et al. 2010). The native 
MLSA was prepared as previously described (Marques 
et al. 1998). LAM was purified from whole M. leprae 
cells as previously described (Torrelles et al. 2004). Cer-
tain CSU-produced recombinant proteins, native MLSA, 
ND-O-BSA and LepLAM are available through the Bio-
defense and Emerging Infections Research Resources 
Repository (beiresources.org/TBVTRMResearchMate-
rials/tabid/1431/Default.aspx).
Western blot analysis - Approximately 0.25 µg of 
each recombinant protein was separated using 15% 
sodium dodecyl sulfate polyacrylamide gel electro-
phoresis and transferred to nitrocellulose membranes. 
Five micrograms of the native MLSA subcellular frac-
tion were loaded in each lane. The membranes were 
blocked with 1% BSA in phosphate buffered saline 
0.05% Tween 80, probed with individual serum sam-
ples at a 1:5,000 dilution overnight and developed as 
previously described (Spencer et al. 2011). The reactiv-
ity of each serum sample to each of the recombinant 
proteins or MLSA was subjectively graded based on 
the thickness and intensity of the band. Bands given a 
3+ demonstrated the strongest intensity and grades of 
2+ and 1+ showed progressively less intense staining 
or thinner bands. A grade of ± was given to weak, but 
detectable bands and no visible reaction was scored as 
(-). Two readers independently scored the bands with 
few discrepancies (< 5%), which were generally only 
one grade higher or lower. 
ELISA - The recombinant proteins LID-1 and 
ML2028 and the other antigens ND-O-BSA and LAM 
were coated onto high-affinity polystyrene Immulon 
IV 96-well ELISA plates (Dynex Technologies, Chan-
tilly, VA) at 100 ng per well in 100 µL of 0.1 M sodium 
carbonate/bicarbonate buffer, pH 9.6 at 4ºC overnight. 
Serum samples were diluted 1:200 as previously de-
scribed (Spencer et al. 2011). The absorbance at 405 
nm was obtained using a VersaMax Pro plate reader 
(Molecular Devices, Sunnyvale, CA) at 15 min after 
the addition of the substrate. 
RESULTS
Baseline seroreactivity of LP sera against recombi-
nant proteins and native MLSA - We performed Western 
blot analysis of 21 BL/LL and nine BT/TT LP sera sam-
ples to examine their reactivity patterns with 12 recom-
binant proteins and the native M. leprae cytosolic subcel-
lular fraction. The reactivity patterns are shown in Table 
II and representative blots for three BL/LL and three TT/
BT individuals are shown in Fig. 1. The protein antigens 
that showed the strongest overall responses in the BL/
LL group were LID-1 (100%), ML2028 (Ag85B) (100%), 
ML2038 (100%), ML0405 (100%), ML2055 (95%) and 
ML0286 (95%), with LID-1 and ML2028 (Ag85B) 
showing the most intense responses of all recombinant 
proteins tested. Serological reactivity patterns for the 
remaining proteins were weaker and/or more variable 
towards ML0411 (90%), ML0091 (86%), ML0050 (CFP-
10) (86%), ML0380 (10 kDa GroES) (62%), ML0557 
(29%) and ML1795 (0.5%). As expected, the reactivities 
of the TT/BT sera were much weaker than BL/LL sera, 
but some of the antigens were well recognised, including 
ML2028 (100%), ML0286 (100%), ML2038 (100%) and 
LID-1 (78%). Whereas nearly all LL patients recognise 
PGL-I, the strength of the recognition of other protein 
antigens by TT/BT patients is novel. The native cytosolic 
subcellular fraction is mainly used to detect the relative 
intensity of reactivity towards LAM, which is indicat-
ed by a smear in the molecular weight range of 20-40 
kDa. However, other proteins were also detected, such 
as ML0380. For patients classified as BL/LL, 62% rec-
ognised ML0380, while none of the BT/TT cases reacted 
with this protein, which is in accordance with previously 
reported results (Spencer et al. 2011). Approximately 
76% of the BL/LL patient sera showed very strong reac-
tions to LAM (≥ 2+ intensity), while less than half (44%) 
of the TT/BT sera demonstrated this intensity. The inten-
sity of this smear in the 20-40 kDa range by immunob-
lot analysis correlated with the antibody titre to purified 
M. leprae LAM in the ELISA assay. Collectively, these 
results showed that each individual generates unique re-
sponse patterns to various M. leprae antigens and that 
the intensities of the responses to certain antigens are 
predictive of the clinical disease status.
Longitudinal effect of MDT treatment on antibody 
titres against M. leprae antigens - The antibody titres for 
all 12 MB index cases were determined by Western blot 
analysis and ELISA to examine the changes in responses 
to recombinant protein antigens, PGL-I and LAM over 
the two-year observation period. The Western blotting 
results for three of these individuals towards the four 
recombinant proteins (LID-1, ML2055, ML2028 and 
ML0050) and native MLSA, which provided the stron-
gest reactions that changed the most over time, are pre-
sented in detail in Fig. 2 and the corresponding ELISA 
results are shown in Fig. 3.
Case MB-1 was initially diagnosed with BL leprosy 
with a BI of 4.0+, which was reduced slightly to 3.7+ after 
one year of MDT. The treatment course was uneventful 
with no reactional episodes. The initial titres against all 
four recombinant proteins and native MLSA were very 
TABLE I
Sample group characteristics
Sample  
category
Male  
(n)
Female  
(n)
Median age  
(range)
BI  
(range)
MBa (12) 10 2 27 (18-69) 1.7+ - 4.7+
PBb (6) 4 2 39 (35-49) 0
HHC (51) 23 28 22 (9-62) NA
a: 10 lepromatous and two borderline lepromatous, all with > 
six countable lesions; b: six borderline tuberculoid, all with 
one or two countable lesions; NA: not available.
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strong and did not appear to significantly decrease dur-
ing the first six months of therapy. The antibody titres 
to these proteins did decrease to a greater extent by 24 
months, with the reactivity against ML2028 and ML0050 
decreasing the most, as shown by immunoblot (Fig. 2A). 
The decrease in titre towards LID-1 is shown in the ELI-
SA assay by a decrease in optical density (OD) from 1.20 
at baseline to 0.77 one year after the end of MDT (Fig. 
3A). However, the antibody titres to PGL-I and LAM in 
this individual show little, if any, decrease by ELISA. 
Case MB-2 was diagnosed with LL disease with a 
BI of 3.5+, which was reduced to 2.5+ after complet-
ing one year of MDT. This individual had several type 
1 reversal reactions at months 1, 9 and 12 and received 
palliative steroid treatment in each instance to dampen 
the inflammatory response. The intensities of the West-
ern blot bands corresponding to the protein antigens 
LID-1, ML2055 and ML2028 increased significantly 
from baseline to one month after beginning MDT, which 
was likely the result of the reactional episode (Fig. 2B). 
Reactional episodes are often linked to successful treat-
ment, in which death of the bacilli causes a release of 
antigens and stimulates cell-mediated and antibody im-
mune responses. After this initial spike in antibody titres 
to the protein antigens, the antibody response stabilised 
to a slightly lower level one year after ending MDT. 
TABLE II
Western blot reactivity patterns of recombinant Mycobacterium leprae proteins and native M. leprae soluble antigen (MLSA)  
with 21 boderline lepromatous (BL)/lepromatous (LL), nine borderline tuberculoid (BT)/tuberculoid (TT)  
and nonendemic control (NEC) serum samples to identify the best antigen candidates for screening by Western blot
BI ID 0411 LID-1 2055 0286 2028 0091 0405 0557 2038 1795 0050 0380 MLSA
6+ LL38 ++ +++ ++ + ++ ± ++ – ++ – +++ ++ +++
5+ LL12 + +++ ++ + +++ + ++ ++ ++ ± + +++ +++
6+ LL31 ++ +++ ± + +++ ± ++ – + – ++ – +++
5+ LL39 ++ +++ ++ + +++ ± ++ – +++ – ++ + ++
6+ LL4 ± +++ ++ – ++ ± ++ – + – ± +++ +
6+ LL22 + +++ ++ + +++ + ++ – ++ – ++ ++ +++
5+ LL27 ± +++ ++ + +++ + ++ + ++ – ± ++ ++
5+ LL19 ++ +++ ++ + +++ + ++ – ++ – ± ++ +
5+ BL11 ++ +++ ++ + +++ + ++ – ++ – +++ + ++
4.0+ MB-1 + +++ ++ ± +++ + ++ – + – +++ – +++
3.5+ MB-2 + +++ ++ ± + + ++ ± + – ± ± +
3.2+ MB-3 ++ +++ ++ ± + ++ ++ – + – ± – +
4.33+ MB-4 – +++ ++ ± ++ + ++ – + – + – ++
4.7+ MB-5 ± ++ + ± +++ – ++ – + – – + ++
3.8+ MB-6 + +++ ++ + + ± ++ ± + – ++ – +++
1.7+ MB-7 ± +++ – + + – ++ – + – ± – +++
2.83+ MB-8 – ± ++ + + – ± – + – – – ++
4.0+ MB-9 + +++ ++ + ++ + ++ ± + – ++ + +++
3.33+ MB-10 ± +++ ± ± +++ – ++ – + – – – +++
4.33+ MB-11 ++ +++ ++ + +++ + ++ – + – ++ + ++
4.7+ MB-12 + +++ ++ + +++ ++ ++ ± ++ – +++ +++ ++
Positive (%) 90 100 95 95 100 86 100 29 100 0.5 86 62 100
0 BT53 ± ± – + + – ± – + – – – +++
0 BT57 – ± ± + + – – – + – ± – +++
0 TT51 – ± – + + – ± – + – ± – +
0 PB-1 – ± – + + – ± – + – ± – +++
0 PB-2 – + – + + – ± – + – – – –
0 PB-3 – – – ± + – – – + – – – +
0 PB-4 – – ± ± + – – + + – – – +
0 PB-5 – ± – + ++ – – – + – ± – ++
0 PB-6 – ± ± ++ + – – – + – – – +
Positive (%) 11 78 33 100 100 0 44 11 100 0 44 0 89
NA NEC14 – – – – – – – – – – – – –
reactivity ranked from very strong (+++) to weak (±) to negative (–). BI: bacterial index; ID:identification; LID-1: leprosy IDRI diagnostic; 
MB: multibacillary; NA: not available; PB: paucibacillary.
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However, the responses to PGL-I and particularly LAM 
showed unexpected increases by Western blotting (Fig. 
2B, panel at 24 months) and ELISA (Fig. 3B). 
Case MB-3 was initially diagnosed with BL disease 
with a BI of 3.2+, which was reduced by almost two logs 
to 1.33+ after one year of MDT. This patient experienced 
neuritis during early MDT and was treated with low dose 
steroids, which were tapered off by six months, without 
the occurrence of an explicit reactional episode. The 
patient’s titres against the protein antigens LID-1 and 
ML2055 were particularly strong at baseline, but showed 
markedly decreased intensities by six months after be-
ginning MDT and were barely detectable at 24 months 
(Fig. 2C). The response to ML0050 was detectable before 
treatment initiation, but disappeared by month 3. During 
this same time period, this patient experienced clearance 
of skin lesions after only a few months of treatment. 
ELISA results showing the antibody titres against 
LID-1, PGL-I (ND-O-BSA) and LAM over the two-year 
period for these same three patients are shown in Fig. 3. 
Patient MB-1 had a slight decrease in the titres against 
PGL-I and LAM (8% and 4%, respectively), whereas there 
was a more marked decline in the titre against LID-1 with 
a baseline OD of 1.20 that decreased by 36% to 0.77 at the 
end of two years. Patient MB-2 showed a steady decrease 
in the response to LID-1 from OD 0.95-0.51, but this pa-
tient’s anti-PGL-I titre was stable from six-24 months. 
The anti-LAM titre increased during the last 12 months 
of observation from OD 1.57-1.90. For patient MB-3, there 
were marked decreases in the titres against all three anti-
gens, particularly during the first three months of drug 
therapy. The titres against PGL-I and LAM decreased by 
46% and 51%, respectively, while that against LID-I de-
clined by 65% over the 24-month period. 
Overall, these results indicate that the antibody re-
sponse to protein antigens declines more rapidly over 
time, while the responses against carbohydrate and 
glycolipid antigens tend to decay more slowly or even 
remain elevated, particularly in individuals with a very 
high initial bacillary load. 
 
Assessment of antibody responses in 51 healthy HHC 
over a two-year period - Healthy HHC were enrolled af-
ter each index case was diagnosed and a baseline bleed 
was obtained. The reactivities of the antibodies in the 
baseline samples against three key antigens, including 
LID-1 (which had been shown in a previous study to 
elicit a positive antibody response in individuals who 
were diagnosed with clinical leprosy up to one year prior 
to the onset of disease symptoms) (Duthie et al. 2007), 
ML2028 (Ag85B) and native MLSA, which was exam-
ined to assess reactivity against LAM, were determined 
by Western blot analysis, as shown in Fig. 4. Responses 
against the protein antigens LID-1 and ML2028 were 
much weaker than those observed in the MB index cases 
(index case MB-12 is included in Fig. 4 as an example), 
although the HHCs frequently demonstrated strong titres 
against LAM. The initial assessment of baseline reactiv-
ity patterns by Western blot analysis showed responses 
of ≥ 1 against LID-1 (8/51 HHCs, 16%), ML2028 (23/51, 
45%) and MLSA (14/51, 27%). Two of these individuals, 
HHC 12-2 and HHC 18-2, showed much stronger reac-
tivity (2+) towards both LID-1 and ML2028 compared 
to other HHC, whereas these subjects demonstrated only 
weak reactivity with MLSA. The antibody titres against 
LAM and PGL-I were determined by ELISA for 48 of 
these HHC (3 individuals did not have complete follow-
up serum samples taken) for up to eight serial bleeds 
over the 24-month period. No change or slight decreas-
es in the titres against LAM or PGL-I were observed 
in 41/48 (85%) of these individuals, while seven HHC 
showed some increase in their response against one of 
these antigens. The antigen reactivity patterns of these 
seven HHC were re-evaluated to identify changes in 
reactivity against LID-I, ML2028 and MLSA between 
baseline and later samplings. Two of these individuals 
showed increased reactivities against the protein anti-
gens PGL-I and LAM. HHC 5-1 had a very strong titre 
against LAM by immunoblot at baseline and this titre 
increased somewhat by ELISA and immunoblot at 21 
months. More importantly, this patient demonstrated re-
activity against the 10 kDa GroES protein (ML0380) in 
MLSA at baseline and this titre increased considerably 
at 21 months. Antibodies to this protein are found in > 
50% of MB patients, but is negative in all PB individuals 
we have examined to date. Thus, a positive response to 
ML0380 in a HHC would likely place this individual in a 
higher risk category and necessitate close monitoring for 
signs of the disease. The second subject with increased 
reactivities described above, HHC 18-1, showed a sub-
stantial increase in the anti-LAM titre at 15 months with 
a corresponding increase in reactivity against LID-1 by 
immunoblot. At the time of submission, the disease sta-
tus of these individuals remained unchanged. 
 
Fig. 1: Western blots of 12 recombinant proteins and the native My-
cobacterium leprae cytosolic protein probed with three representa-
tive lepromatous [multibacillary (MB)-12, MB-11 and MB-10] and 
three tuberculoid [paucibacillary (PB)-1, PB-4 and PB-6] leprosy 
patient serum samples. Approximately 0.25 µg of each recombinant 
protein and 2.5 µg of M. leprae soluble antigen (MLSA) were run in 
individual Lanes: 1: ML0411, 45 kDa serine rich antigen; 2: leprosy 
IDRI diagnostic (LID-1) fusion protein; 3: ML2055, 29.6 kDa modD; 
4: ML0286, 36.7 kDa fructose bisphosphate aldolase; 5: ML2028, 
34.8 kDa Ag85B; 6: ML0091, 28 kDa antigen precursor; 7: ML0405, 
23.8 kDa conserved hypothetical protein (part of LID-1); 8: ML0557, 
24.9 kDa lprG lipoprotein; 9: ML2038, 18.3 kDa bacterioferritin; 10: 
ML1795, 18 kDa heat shock protein; 11: ML0050, 10.9 kDa CFP-10; 
12: ML0380, 10.8 kDa GroES chaperonin; 13: native MLSA. Blots 
were probed with a 1:5,000 dilution of patient serum. 
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Further analysis of HHC 12-2 and HHC 18-2 over 
a two-year period - Because antibody titres to LID-1 
have previously been shown to increase prior to clinical 
diagnosis (Duthie et al. 2007) we were especially inter-
ested in those HHCs who showed stronger reactivities 
against this antigen. HHC 12-2 and HHC 18-2 showed 
the strongest responses against LID-1 and ML2028 at 
baseline. Analysis of serial serum samples from HHC 
18-2 showed no change in the strength of the response to 
LID-1 or ML2028, but showed a decrease in the response 
to LAM (data not shown). In the case of HHC 12-2, West-
ern blot analysis of serial bleeds taken over the course of 
15 months showed no change in the strength of the re-
sponse to LID-1 or ML2028, but there was an increase in 
the antibody titre against MLSA (specifically against the 
20-40 kDa region associated with LAM reactivity) at six 
months. This response grew progressively stronger with 
each three-month interval (Fig. 5A). Further analysis of 
the serial serum samples by ELISA confirmed that while 
the OD corresponding to the response against ML2028 
remained essentially unchanged, the results measuring 
the responses against both anti-PGL-I and anti-LAM 
showed a progressive increase from the baseline OD of 
approximately 0.30 to a final OD of greater than 1.60 
(Fig. 5B). The increasing titre in this individual was re-
ported to the director of the clinic (MFB) in April 2011. 
Two months later, this individual was confirmed to have 
BL leprosy with a bacillary load of 1.7+ on a routine 
follow-up visit. Because this diagnosis was made early 
when the bacillary load was still relatively low and MDT 
was immediately initiated, it is likely that further dam-
age or neurological impairment was prevented.
Evidence that treatment of the index case influences 
antibody titres in HHCs - In addition to examining all 
serial bleeds for changes in antibody titres to PGL-I and 
LAM by ELISA, the baseline and final serum samples 
from each HHC were probed against LID-1, ML2028 and 
MLSA by Western blot analysis to identify any changes 
in antibody titres in HHCs once the index case in the 
household completed MDT. In 17/51 HHCs (33%), there 
was a detectable decrease in the reactivity against one 
or more antigens. The results obtained from four HHCs 
(Fig. 6) showed marked decreases in reactivity against 
ML2028 and two individuals (HHC6-2 and HHC12-3) 
showed decreased reactivities towards LAM. Notably, 
HHC12-1 and HHC12-3 showed decreased responses 
to these antigens, whereas HHC12-2, a sibling of index 
case MB-12, was the only individual who developed a 
rapidly rising titre and progressed to clinical disease. 
DISCUSSION
Clinical examination and bacteriological and histo-
logical findings continue to be the methods of choice for 
the diagnosis and follow-up care of LPs. The availability 
of better tools for clinicians and health care workers to as-
sign the proper treatment regimen, monitor the efficacy 
of therapy, detect disease relapse and identify biomarkers 
of infection and disease progression in individuals most 
at risk for developing this disease, particularly for con-
tacts of MB index cases, is sorely needed. The presence 
of IgM antibodies to the M. leprae-specific PGL-I has 
been used in the past to classify patients for treatment 
purposes (Bührer-Sékula et al. 2003) and the magnitude 
of the antibody titre correlates strongly with the bacillary 
load. However, detection of the anti-PGL-I antibody in 
those at the tuberculoid end of the spectrum (TT/BT) is 
low, usually approximately 20-40%. Recent studies have 
shown that responses to protein antigens can be used to 
characterise this disease. A number of these antigens, in-
cluding ML2028, ML2038 (Spencer et al. 2011) and the 
fusion protein LID-1 (Duthie et al. 2010, 2011) have been 
shown to induce very strong antibody responses in virtu-
ally all BL/LL cases. A previous study in which HHCs of 
MB patients were bled four years prior to clinical diag-
nosis showed that seven/11 (64%) developed antibody re-
Fig. 2: Western blot of four recombinant proteins and Mycobacterium leprae cytosolic protein, M. leprae soluble antigen (MLSA), probed 
with serial serum samples from three index cases at baseline and up to 24 months after multidrug therapy. Lane 1: leprosy IDRI diagnostic; 2: 
ML2055; 3: ML2028; 4: ML0050; 5: native MLSA; A: multibacillary (MB)-1, initial bacterial index (BI) of 4.0+; B: MB-2, initial BI of 3.5+, 
with reversal reactions at months 1, 9 and 12; C: MB-3, initial BI of 3.2+.
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A number of studies have shown that family members 
living in close contact with an untreated MB index case 
have the highest risk for developing this disease (Fine et 
al. 1997, Cunanan et al. 1998, van Beers et al. 1999). In 
a large study involving 1,396 HHCs of index cases (79% 
of the index cases were MB) in Uberlândia, Brazil over 
a five-year period, 28 individuals were eventually diag-
nosed with leprosy, with 75% of those cases occurring 
within the first year of enrolment (Goulart et al. 2008). 
Thus, the percentage of HHCs who eventually devel-
oped the disease was 2%, as was the case in our study 
to date. All HHCs were assessed for the absence or pres-
ence of a BCG scar, Mitsuda skin reaction by lepromin 
injection and antibody titre to PGL-I. It was determined 
that the individuals at highest risk, with a combined risk 
factor of 24.5, were those who showed positive PGL-I 
antibody responses and were negative for a BCG scar 
and Mitsuda reaction. However, demonstrating a posi-
tive anti-PGL-I response indicated a relative risk that 
was approximately six-fold higher for the occurrence of 
the disease. Additional risk factors for leprosy in HHCs 
have been identified in a large prospective cohort study 
of 21,870 contacts of newly diagnosed LPs in northwest 
Bangladesh called the COLEP study (Moet et al. 2008). 
The risk factors identified in this study include contact 
with cases of PB leprosy with two-five lesions or MB 
disease, physical closeness, such as residing within the 
Fig. 3: ELISA assay of serial serum samples from three index cases 
at baseline and up to 24 months after beginning multidrug therapy 
to show the effect of treatment on antibody titre to leprosy IDRI di-
agnostic (LID-1) (closed square), ND-O-BSA (phenolic glycolipid-I) 
(closed circle), and LepLAM (closed triangle). A: patient multibacil-
lary (MB)-1; B: patient MB-2; C: patient MB-3. OD: optical density.
sponses to LID-1 up to one year prior to the development 
of clinical symptoms. These antibody titres were higher 
and occurred much sooner than the increases in the anti-
PGL-I IgM responses observed in the same individuals 
(Duthie et al. 2007). It was also shown that a heightened 
IgG titre against LID-1 was a good indicator of early in-
fection and active disease, as titres remained low or un-
detectable in contacts who did not progress to disease. 
Our study indicates that a strong response to LID-1 and 
ML2028 may represent a biomarker of disease progres-
sion because a contact that developed leprosy (HHC12-2) 
showed the strongest response to both of these antigens 
19 months before clinical diagnosis. Nevertheless, the 
antibody titres against LID-1 and ML2028 remained 
static from baseline through 15 months, whereas those 
against PGL-I and LAM increased significantly starting 
at six months. The increased titres against these protein 
antigens are likely dependent on the bacterial load, as 
increased band intensity by Western blot analysis or sig-
nificant elevation in the ELISA signal against these two 
antigens occurred in the individuals with BIs greater than 
3.0. However, there was significant variability in these 
responses among MB cases. MB-7, who had a BI of only 
1.7+, had a very strong 3+ reaction to LID-1 compared 
to MB-8, who had a BI of 2.83+ and whose reactivity to 
LID-1 was weakly positive (±). 
Fig. 4: baseline Western blot reactivity patterns of 51 healthy house-
hold contact (HHC) of multibacillary (MB) leprosy patients against 
leprosy IDRI diagnostic (LID-1) (Lane 1), ML2028 (Lane 2) and na-
tive Mycobacterium leprae soluble antigen (Lane 3). Contacts hav-
ing strong reactivity against both LID-1 and ML2028 (HHC12-2 and 
HHC18-2) are labelled with an asterisk. Nonendemic control (NEC)14 
is a representative NEC healthy serum and MB-12 is the baseline re-
activity of a representative index case. 
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same household, age, with the highest risk associated 
with those 15-20 years of age and those older than age 
30, thereby representing a bimodal distribution and ge-
netic relation, as in the case of parents and their children 
or consanguineous siblings living together within the 
same household (Moet et al. 2006). 
In our study, index case MB-12 had a very high BI 
at diagnosis (4.7+) with over 20 countable lesions. This 
patient was diagnosed in late 2009, but was thought to 
have had clinical disease for up to five years previously 
and lived in a household with three blood-related HHCs 
for over 12 years. Despite these facts, it was not until 19 
months after enrolment that HHC12-2 showed clinical dis-
ease signs and was diagnosed. The PGL-I and LAM anti-
body titres had substantially increased for more than one 
year prior to diagnosis. Interestingly, the other two fam-
ily members in this household, HHC12-1 and HHC12-3, 
showed decreasing titres against both antigens by ELISA 
and Western blotting. One likely explanation for this de-
crease is that the main source of M. leprae exposure in 
the household was essentially removed soon after the in-
dex case began MDT. It is thought that constant shedding 
of viable M. leprae bacilli from the nasal secretions of 
untreated LL cases, estimated to be on the order of up to 
107 bacilli per day (Davey & Rees 1974), would result in 
the continuous exposure and/or re-infection of contacts 
residing in the household. Repeated exposure to high 
bacillary loads causes an increase in both cell-mediated 
immunity and antibody titres to M. leprae antigens (Mar-
tins et al. 2012, Geluk et al. 2012). However, treatment of 
the index case would cause a rapid cessation of shedding 
of viable bacilli, eventually eliminating exposure to my-
cobacterial antigens within the household. In the absence 
of this antigenic stimulus, one would expect the antibody 
titre to wane. Thus, effective treatment of the index case 
can have a spillover effect on the antibody responses of 
those closest to this individual, resulting in a measurable 
decrease in the antibody titres in HHCs over time. The 
fact that a measurable decrease in antibody titre to one 
or more antigens was detected in one third of all HHCs 
could be interpreted as a clear indication of the impact of 
the successful treatment of index cases. 
Although there was a rapid rise in the antibody titres 
against PGL-I and LAM beginning at six months in 
HHC12-2, the antibody responses to LID-1 and ML2028 
were unchanged for 15 months as detected by Western 
blotting and ELISA. When one compares these values 
with the antibody responses in the index case MB-12, it 
might be predicted that the very high IgG titres against 
LID-1 and ML2028 in individuals with very high BIs 
likely evolved over a long period of time, perhaps over 
the course of several years. During disease progression, 
the point at which the bacillary load may exceed a certain 
tipping point to cause a similar increase in the IgG titres 
against protein antigens remains unclear. At the time of 
diagnosis, the BI of HHC12-2 was only 1.7+, whereas the 
BI for index case MB-12 was 4.7+, indicating a 1,000-fold 
higher bacillary load. One can calculate what this bacte-
Fig. 5: Western blot and ELISA assay results of serial bleeds of house-
hold contact 12-2 showing increase in antibody titre to lipoarabino-
mannan (LAM) and phenolic glycolipid-I. A: Western blot of recom-
binant protein ML2028 (Lane 1) and Mycobacterium leprae soluble 
antigen (Lane 2) with serum samples from baseline through 15 months 
after enrolment. The reactivity with leprosy IDRI diagnostic was the 
same intensity as ML2028 and also did not change over time (data 
not shown); B: ELISA assay of the same serum samples showing the 
optical density (OD) against ML2028 (Ag85), ND-O-BSA, and M. 
leprae LAM.
Fig. 6: Western blot of four household contact (HHC) (HHC6-2, HHC12-1, HHC12-3 and HHC4-1) against leprosy IDRI diagnostic (LID-1), 
ML2028 and Mycobacterium leprae soluble antigen (MLSA) at the beginning of enrolment (baseline) and towards the end of the study showing 
a decrease in reactivity towards one or more antigens over time. Lane 1: LID-1; 2: ML2028; 3: MLSA. 
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rial burden represents by assuming that a BI of 1.0 repre-
sents approximately 104 bacilli per gram of tissue (J Bar-
reto, unpublished observations), therefore assuming that 
a BI of 4.7 would be 1,700 times more than a BI of 1.0. 
Assuming that 2.0 x 109 bacilli weigh 1 mg and that skin 
represents 20% of body weight, an individual weighing 
70 kg with a BI of 4.7+ would be carrying roughly 0.5 
kg of M. leprae throughout his body. It is not surprising 
that this staggering amount of bacilli causes the extreme-
ly high antibody responses to protein, carbohydrate and 
glycolipid antigens in individuals with very high BIs.
The presence of IgM serum antibodies to PGL-I in 
LPs has been shown to have potential for classifying pa-
tients for treatment purposes, case monitoring, identifi-
cation of the risk of relapse and identification of HHCs 
with a higher risk of developing the disease (Oskam 
et al. 2003, Bührer-Sékula et al. 2003, de Moura et al. 
2008). However, the vast majority of PB leprosy cases 
do not develop detectable antibodies to PGL-I and in 
areas where leprosy is hyperendemic, as in the Brazil-
ian Amazon in northeastern Brazil, greater than 50% of 
young schoolchildren surveyed in some provinces had 
positive anti-PGL-I responses (Barreto et al. 2011, Sal-
gado et al. 2012). A number of recent reports have shown 
that IgG responses to protein antigens could be used as 
supplemental tools in the development of serological 
tests to diagnose leprosy, monitor treatment and detect 
relapse after treatment (Duthie et al. 2011, Geluk et al. 
2011). The titres of IgG antibodies to protein antigens 
generally correlate with the bacterial load and strong re-
sponses in MB patients can rival anti-PGL-I responses. 
The best protein candidates to assess the IgG response 
include ML0405, ML2331, ML2055 (Reece et al. 2006, 
Duthie et al. 2007), ML2028 (Launois et al. 1994, Spen-
cer et al. 2011) and ML2038 (Maeda et al. 2007, Kai et 
al. 2008, Spencer et al. 2011). A bioinformatics analysis 
predicted ML0405 to be one of the most promiscuous 
M. leprae proteins studied to date and to contain T cell 
epitopes predicted to be recognised by 50 out of 51 hu-
man leukocyte antigen-DR alleles along with seven po-
tential T cell epitopes and 39 potential B cell epitopes, 
whereas ML2331 contained 24 potential B cell epitopes 
(Sampaio et al. 2011). The engineering of these two pro-
teins into the fusion protein LID-1 has been shown to 
be effective in detecting antibody responses in virtually 
all MB patients, with specificity and sensitivity of 87% 
(Duthie et al. 2007). IgG antibody responses to LID-1 
were detected a year in advance of disease symptoms in 
seven/11 HHCs of MB patients (64%) who were even-
tually diagnosed with leprosy. These responses were 
strikingly more elevated and occurred much earlier 
than the increases in the anti-PGL-I IgM responses in 
the same individuals (Duthie et al. 2007). Nevertheless, 
the responses to LID-1 in PB individuals were compara-
tively weak. Therefore, work to identify other proteins 
that are better recognised at the tuberculoid end of the 
spectrum is on-going. In this study, we confirmed that 
ML2028 and ML2038 were recognised by almost all PB 
patient sera. In addition, one of the new antigens tested, 
ML0286, was similarly recognised by all MB and PB 
patient sera. This protein, a 1,6-fructose bisphosphate 
aldolase (Rv0363c, fba ortholog in Mycobacterium tu-
berculosis), was recently shown to be important in the 
glycolytic/gluconeogenic pathway in M. tuberculosis, 
is produced under various axenic growth conditions, 
including oxygen deprivation, and was found to be ex-
pressed in the necrotic core of primary lung granulomas 
in infected guinea pigs. Thus, this protein may play an 
important role in nonreplicating bacilli during latent in-
fection (de la Paz Santangelo et al. 2011). Interestingly, 
ML0286 was also detected in subcellular fractions of 
armadillo-derived M. leprae grown in vivo and had pre-
viously been identified by proteomic analysis of the M. 
leprae cytosolic protein fraction (Marques et al. 2004). 
It may be possible to engineer epitopes from these three 
proteins (ML2028, ML2038 and ML0286) into a fusion 
protein that is well recognised by PB patients in the same 
way that LID-1 was engineered.
The results of our study indicate that the detection 
of antibody responses to M. leprae protein antigens 
provides an added benefit to monitoring anti-PGL-I re-
sponses alone in HHCs who are most at risk of devel-
oping leprosy. Although sensitive, the use of Western 
blotting as a screening tool to assess antibody titres in 
HHCs is not practical. Alternatively, an ELISA for the 
high-throughput analysis of large numbers of samples 
that incorporates antigens (perhaps as a fusion protein in-
corporating multiple protein epitopes) recognised by MB 
and PB individuals is still in the developmental stage. 
The development of a rapid protein-based serological 
assay could be used in nonspecialised settings, such as 
field conditions, especially in areas where leprosy is still 
hyperendemic, to more rapidly identify early signs of this 
disease. Because the majority of HHCs develop a protec-
tive immune response and do not progress to disease, a 
large-scale prospective longitudinal study in HHCs and 
healthy controls from a hyperendemic region would be 
critical to determine whether the biomarkers identified in 
this study can be used as additional tools to more readily 
predict disease at an early stage as we have shown here, 
allowing for treatment that would effectively lower dis-
ease prevalence and reduce grade-2 disability.
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